The FDA’s latest innovation signals reveal how regulatory systems are evolving—and what FDA regulatory innovation may increasingly require from industry.

TL;DR: FDA’s new Commissioner’s National Priority Voucher (CNPV) program  accelerates reviews to ~1–2 months for products that advance U.S. national priorities: big-burden diseases, public-health crises, affordability, and on-shored manufacturing. If you’re heading into this pathway, success hinges on early CMC and labeling completeness, disciplined traceability, and an operating model built for rapid, team-based review.   What’s inside the program  Why it exists:  Speed acce